EnzyMAP AI – a symbiosis of enzyme development and AI
David Schönauer
Enzymes are an essential part of today’s life as their use enabled products like lactose-free cheese, more sustainable processes like doing laundry at room temperature, improved nutrition for farm animals and especially more efficient processes to produce pharmaceuticals. Adopting natural enzymes to such man-made workflows via genetic engineering is expensive and risky yet mandatory to maintain commercial viability. Applying artificial intelligence to enzyme development may drastically reduce research efforts and risks and accelerate the creation of enzymes with superior performance. The talk will showcase how Aminoverse brought enzyme development to the next level with its proprietary AI platform ‘EnzyMAP AI’.
Biography
David started his entrepreneurial career in 2012 as he was appointed CEO of the german start-up SeSaM-Biotech GmbH. He ran the company specialized in enzyme development by Directed Evolution in parallel to his studies at RWTH Aachen University, Germany, where he gradudated in 2014 in Molecular and Applied Biotechnology among the top 5% of all university students of the year. Having grown SeSaM-Biotech organically from 1 to 10 employees over 7.5 years, David took the next step by founding Aminoverse in March 2020, a company that combines enzyme development with artificial intelligence to advance biotechnology for people and the planet.
